​​​​​​​Big Pharma might not like billionaire John Arnold’s latest move any more than they did his first. After helping cost-effectiveness watchdog ICER get…

When the week began, Stada had plenty of interested suitors, but it wasn’t sure any of them would make a real offer. Now, the first has come in at $3.72…

Biosimilar competition for Amgen’s blockbuster rheumatoid arthritis drug Enbrel is lurking in the background, but the biotech may have found a way to help…

Pharma’s top U.S. execs haven’t been shy about expressing their desire for tax reform—and now, they’re taking those wishes directly to Congress.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

If all baby boomers got tested for hep C, that could help stem freefall of Gilead's blockbusters—and it's exactly the move the company is…

Activist investors have moved in on Bristol-Myers Squibb, including Carl Icahn, who has a long history of pushing drugmakers to put themselves on the block.

This year’s flu vaccine is working for almost half of recipients, the CDC says in an update on what it’s calling a “moderate” season.

J&J is the most admired pharma company, according to Fortune's annual corporate poll, for the fourth year in a row and comes in at No. 13 among all…